Icon Bioscience said today that the FDA accepted the company’s submitted new drug application for its Dexycu drug designed to be used as an anti-inflammatory following cataract surgery.
The Newark, Calif.-based company’s Dexycu utilizes the company’s Verisome novel drug delivery system designed to treat ophthalmic diseases and slowly release the drug while the Verisome system simultaneously degrades, according to the company’s site.
Read the whole story at our sister site, Drug Delivery Business
The post Icon Bioscience touts FDA NDA submission for Dexycu appeared first on MassDevice.
from MassDevice http://ift.tt/2sUi3M5
Cap comentari:
Publica un comentari a l'entrada